Psoriasis Clinical Trial

Alefacept Mechanism of Action in Psoriasis

Summary

To determine the mechanism of action of alefacept in patients with psoriasis.

View Full Description

Full Description

The purpose of the study is to better understand the mechanism of action of an FDA approved drug (alefacept). Subjects enrolled will be given alefacept 7.5 mg intravenously on a weekly basis for 12 weeks. Response is assessed by improvement in the PASI score. The responders will get no further treatment and the nonresponders will receive additional 4 weeks of therapy. Skin biopsies will be obtained throughout the study and T-cell apoptosis will be correlated to clinical response. There is no placebo group. The duration of the study is approximately 1 year.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Alefacept is indicated for the treatment of adult patients (18 years or older) with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. Patients must have at least one plaque of least 2.5 cm in diameter (for biopsies).

Exclusion Criteria

CD4 < 400/ml
WBC less than lower level of normal for the reporting laboratory
< 5% Body Surface Area involved with psoriasis
Serious infection e.g., latent or active tuberculosis
History of AIDS or Hepatitis B,C, all internal cancers, lymphoma, untreated cutaneous basal or squamous cell carcinoma
Systemic anti-psoriasis medications and phototherapy within 28 days of the first dose of Alefacept
Topical anti-psoriasis medications within 14 days of the first dose of Alefacept, except for moisturizers, tar shampoos (exception, Elidel is permitted to be applied on the face, groin and axillae areas. These areas are not biopsied.)
Inability to understand consent form or comply with study requirements
Pregnancy or lactation
Concurrent medical illness that would make participation in this clinical trial ill-advised
Any contraindications to using alefacept

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

9

Study ID:

NCT00150982

Recruitment Status:

Completed

Sponsor:

University of Medicine and Dentistry of New Jersey

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UMDNJ Clinical Research Center
New Brunswick New Jersey, 08903, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

9

Study ID:

NCT00150982

Recruitment Status:

Completed

Sponsor:


University of Medicine and Dentistry of New Jersey

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider